Conclusion
TNBC
The addition of carboplatin to standard NACT in stages II and III TNBC was associated with a non-statistically significant numerical increase in the pCR rate of 13.7%, consistent with other similar clinical trials. Follow-up for survival outcomes and translational research initiatives are ongoing. Given the consistent results with previous studies, the addition of carboplatin appears to have a favorable risk-to-benefit profile. It might be considered a potential NACT component for patients with high-risk TNBC in LMIC.